Abstract
The present industry update covers the period 1 February-28 February 2022, with information sourced from company press releases, regulatory and patent agencies and the scientific literature. February is traditionally reporting season for companies, as well as reports on the market situation and its future forecast development coming out. This February also saw some on combination products and smart drug delivery. On smart drug delivery devices next to smart pills companies such as Beta Bionics, Insulet and Tandem Diabetes Care, all in the field of wearable diabetes care, reported progress on their smart wearable, in part closed-loop, insulin injection devices controlled by the patient's smartphone. Another expanding area of innovation is drug-eluting implants such as Ocular therapeutics for the eye, Fondazione and Concept Medical with drug-eluting stents and UroGen and Merz/Vensica Therapeutics combining minimally invasive procedures with enhanced drug delivery. Finally, the increased use of nanobodies and hydrogels (Nanoform, Code Biotherapeutics and Tokyo University of Science) rounds up the picture of a never-ending combination of drugs, innovative formulations and device combinations.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
